Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MMP9 | P14780 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 16/20 | 0.41 |
| ▸ | CA2 | P00918 | 16/20 | 0.41 |
| ▸ | CA9 | Q16790 | 14/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.40 |
| ▸ | CA7 | P43166 | 4/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.40 |
| ▸ | CA3 | P07451 | 3/20 | 0.40 |
| ▸ | CA4 | P22748 | 3/20 | 0.40 |
| ▸ | CA6 | P23280 | 3/20 | 0.40 |
| ▸ | CA5A | P35218 | 3/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17022249 | 0.98 | TSHR (0.68) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL922974 | 0.95 | TSHR (0.64) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL992170 | 0.85 | TSHR (0.55) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| Busulfan SCHEMBL4373 | 0.84 | TSHR (1.00) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| Busulfan SCHEMBL4764696 | 0.84 | TSHR (1.00) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL15151047 | 0.84 | TSHR (0.68) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL23833996 | 0.83 | TSHR (0.52) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL17022252 | 0.83 | TSHR (0.52) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL5174514 | 0.83 | TSHR (0.52) | TSHRKDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL16140792 | 0.83 | TSHR (0.52) | TSHRKDM4EUSP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3871674-B1 | USE OF ANATABINE FOR REDUCING BLOOD SERUM LEVELS OF C-REACTIVE PROTEIN IN AN INDIVIDUAL | PHILIP MORRIS PRODUCTS SA (CH) | 2024-12-25 | — | — | EP | disclosed |
| EP-2549995-B1 | USE OF ANATABINE TO TREAT INFLAMMATION AND METHODS OF SYNTHESIZING ANATABINE | PHILIP MORRIS PRODUCTS SA (CH) | 2021-04-21 | — | — | EP | disclosed |
| EP-3524245-A1 | USE OF ANATABINE TO TREAT INFLAMMATION AND METHODS OF SYNTHESIZING ANATABINE | Philip Morris Products S.A. (CH) | 2019-08-14 | — | — | EP | disclosed |
| EP-3524246-A1 | USE OF ANATABINE TO TREAT INFLAMMATION AND METHODS OF SYNTHESIZING ANATABINE | Philip Morris Products S.A. (CH) | 2019-08-14 | — | — | EP | disclosed |
| US-8557999-B2 | Pharmaceutical, dietary supplement, and food grade salts of anatabine | Rock Creek Pharmaceuticals, Inc. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120232115-A1 | PHARMACEUTICAL, DIETARY SUPPLEMENT, AND FOOD GRADE SALTS OF ANATABINE | Rock Creek Pharmaceuticals, Inc. (US) | 2012-09-13 | — | — | US | disclosed |
| US-8207346-B2 | Methods of synthesizing anatabine | Rock Creek Pharmaceuticals, Inc. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110237627-A1 | METHODS OF SYNTHESIZING ANATABINE | Rock Creek Pharmaceuticals, Inc. (US) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232115-A1 | PHARMACEUTICAL, DIETARY SUPPLEMENT, AND FOOD GRADE SALTS OF ANATABINE | ALKBH1, AADAT, DIMT1 | TSHR 4736/4885KDM4E 972/4885USP2 4055/4885 |
| US-20110237627-A1 | METHODS OF SYNTHESIZING ANATABINE | ALKBH1, ALKBH2, NME2 | TSHR 4821/4885KDM4E 496/4885USP2 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.